COSTIMULATION THROUGH B7-2 (CD86) IS REQUIRED FOR THE INDUCTION OF A LUNG MUCOSAL T-HELPER-CELL-2 (TH2) IMMUNE-RESPONSE AND ALTERED AIRWAY RESPONSIVENESS
S. Tsuyuki et al., COSTIMULATION THROUGH B7-2 (CD86) IS REQUIRED FOR THE INDUCTION OF A LUNG MUCOSAL T-HELPER-CELL-2 (TH2) IMMUNE-RESPONSE AND ALTERED AIRWAY RESPONSIVENESS, The Journal of experimental medicine, 185(9), 1997, pp. 1671-1679
The recruitment of eosinophils into the airways after allergen exposur
e is dependent on interleukin (IL) 5 secreted from antigen-specific CD
4(+) T cells of the T helper cell (Th) 2 subset. However, while it is
established that costimulation through CD28 is required for TCR-mediat
ed activation and IL-2 production, the importance of this mechanism fo
r the induction of a Th2 immune response is less clear. In the present
study, we administered the fusion protein CTLA-4 immunoglobulin (Ig)
into the lungs before allergen provocation to determine whether CD28/C
TLA-4 ligands are required for allergen-induced eosinophil accumulatio
n and the production of Th2 cytokines. Administration of CTLA-4 Ig inh
ibited the recruitment of eosinophils into the lungs by 75% and suppre
ssed ISE in the bronchoalveolar lavage fluid. CTLA-4 Ig also inhibited
the production of IL-4, IL-5, and IL-10 by 70-80% and enhanced interf
eron-gamma production from CD3-T cell receptor-activated lung Thy1.2cells. Allergen exposure upregulated expression of B7-2, but not B7-1,
on B cells from the lung within 24 h. Moreover, airway administration
of an anti-B7-2 monoclonal antibody (mAb) inhibited eosinophil infilt
ration, IgE production, and Th2 cytokine secretion comparable in magni
tude to that observed with CTLA-4 Ig. Treatment with an anti-B7-1 mAb
had a small, but significant effect on eosinophil accumulation, althou
gh was less effective in inhibiting Th2 cytokine production. The anti-
B7-2, but not anti-B7-1, mAb also inhibited antigen-induced airway hyp
erresponsiveness in vivo. In all of the parameters assessed, the combi
nation of both the anti-B7-1 and anti-B7-2 mAb was no more effective t
han anti-B7-2 mAb treatment alone. Wie propose that strategies aimed a
t inhibition of CD28 interactions with B7-2 molecules may represent a
novel therapeutic target for the treatment of lung mucosal allergic in
flammation.